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Abstract
Malignant gliomas are the most common and most malignant tumors of the central ner-
vous system in humans. Median survival of the patients lies between 12 and 14 months
in spite of various available therapy options. Tumor recurrences mostly occur at the mar-
gin of the original tumor volume caused by residual tumor cells. Even better and more
effective resection techniques, which were implemented into the clinic could not help to
improve this situation. A therapy with focus on local effects could help to reduce residual
tumor cells and possibly improve the therapeutic outcome. Since the treatment of brain
tumors is a very difficult intervention and no healthy brain tissue should be damaged, the
therapy should meet also safety aspects.
Photodynamic therapy (PDT) with aminolevulinic acid (ALA) induced protopor-
phyrin IX (PpIX) could comply with the requirements of such a therapy, since several
experimental and clinical studies showed only few side effects occurred performing ALA-
PDT. ALA-PDT is a light-based therapy, in which PpIX, a so called photosensitizer,
accumulates in the target cells and is irradiated with red light. This irradiation activates
the photosensitizer and in the presence of oxygen, this induces a cell toxic effect within
the treated cells. Since in ALA-PDT this phototoxic effect can be limited to tumor cells,
this effect could be the basis of a new and safe therapeutic intervention in neurosurgery.
The effectiveness of the photodynamic effect depends on one hand on the intracellular
concentration of PpIX and oxygen and on the other hand on the intensity and dose of
the irradiated light. When treating humans, it is difficult to increase the intratumoral
concentrations of oxygen or PpIX. Therefore, it seems to be more promising to investi-
gate and improve the light irradiation within the target volume in order to improve the
therapeutic outcome of ALA-PDT.
In the present work, two new concepts of light application in ALA-PDT are presented.
The first concept investigates the so called interstitial light application, where thin light
emitting fibers are placed directly into the tumor volume. The therapeutic light is emitted
at the distal end of the fibers and the active length is up to several centimeters. Before
initiating a first clinical feasibility study, in vivo measurements were performed to deter-
mine the optical tissue properties of brain tumors. Based on the results, comprehensive
optical and thermal calculations were performed. The aim of these calculations was to
understand the light and heat distribution within the tissue under irradiation. From the
results of the calculations, the optimum distances in between the fibers and between fibers
and tumor margin could be deduced. This was done with respect to the fact that a too
short distance could result in unwanted local tissue heating and too long distances could
result in insufficient light intensities in between the fibers or at the tumor margin. A
modified commercial software tool was used to transfer the target positions of the fibers
to updated CT and MRT images. Thus, the absolute positions of the fibers within the
tumor volume were determined and the fibers were placed accordingly with a stereotac-
tic equipment. The distance in between the fibers was determined to be 9 mm and it
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could be shown that at this distance the tissue temperature did not increase above 42 °C.
With this approach, 10 patients were treated within a feasibility study. The tumors of
all patients could be irradiated completely by illuminating the tumor with up 6 fibers
simultaneously. The median tumor volume was 5.9 cm3 and the total applied light dose
was between 4320 J and 11529 J. No side effects were observed and median survival was
15 months. Four patients survived longer than 24 months.
The second concept, which was investigated within the present work, had the intention
to irradiate the photosensitizer with a different wavelength compared to the usually used
red light. The idea was to increase the effectiveness of the PDT by using infrared light,
since light with a longer wavelength has a higher penetration depth in tissue. In principle,
PpIX can be activated also with infrared light, however, the applied light intensities
have to be much higher compared to normal red light PDT. The reason is due to a non
linear effect which is utilized, i.e. two-photon absorption. In two-photon absorption,
the photosensitizers is excited via absorption of two photons with lower energy quasi
simultaneously instead of absorbing one single photon with higher energy and initiates
the phototoxic effect. This approach could be investigated only in cell experiments, since
it is still in a very experimental stage. Cell experiments were done with C6 cells, which
is a rat glioma cell line. Irradiation was performed with pulsed laser light of a titanium-
sapphire laser with a wavelength of 800 nm. Since two-photon absorption needs very
high light intensities, the laser light was focused on the sample surface via several optics.
Cells were incubated with ALA before the irradiation. Cell survival was investigated with
ethium bromide/acrydine orange staining after the treatment. Non incubated cells showed
necrotic areas when light intensity increased 10.9·1010 W/cm2. Since these cells were not
incubated with ALA, this seems to be the lower limit were thermal effects start taking
place. ALA-incubated cells showed necrotic effects already with lower light intensities
(> 6.1·1010 W/cm2). It seems that with these light intensities a phototoxic effect related
with the ALA incubation could be initiated since non incubated cells showed no damage.
The present work intended to investigate new concepts of light application in ALA-
PDT. One of the concepts was still in a very experimental stage and cell experiments
with promising results were performed. The other concept could be implemented into the
clinic and the safety of this treatment modality could be shown in a feasibility study. The
further investigation of both concepts could result in improving ALA-PDT as a treatment
option in neurosurgery.
Zusammenfassung
Maligne Gliome sind die ha¨ufigsten und bo¨sartigsten Tumore des Zentralen Nervensy-
stems beim Menschen. Trotz vielfa¨ltiger therapeutischer Mo¨glichkeiten liegt das mediane
U¨berleben der Patienten derzeit bei 12-14 Monaten. Tumorrezidive treten ha¨ufig lokal an
den Ra¨ndern des urspru¨nglichen Tumorvolumens auf und das trotz verbesserter Resekti-
onsmethoden. Ursache hierfu¨r sind wohl residuale Tumorzellnester, die nicht ausreichend
reseziert werden konnten. Mit verbesserten lokalen Therapien ko¨nnte eine Reduktion die-
ser restlichen Tumorzellen erreicht und dadurch der Therapieerfolg verbessert werden. Da
es sich bei der Behandlung von Gehirntumoren um sehr diffizile Eingriffe handelt und eine
Scha¨digung des umliegenden gesunden Gewebes verhindert werden soll, muss eine solche
Therapieform nicht nur besonders effizient, sondern auch besonders sicher sein.
Die Photodynamische Therapie (PDT) mit Aminola¨vulinsa¨ure (ALA) -induziertem
Protoporphyrin IX (PpIX) ko¨nnte eine solche Therapieform darstellen. Bei der PDT han-
delt es sich um eine Lichttherapie, bei der ein sogenannter Photosensibilisator durch die
Bestrahlung mit Licht aktiviert wird und unter Mitwirkung von Sauerstoff einen toxischen
Prozess in den zu behandelnden Zellen einleitet. Die Sicherheit des Verfahrens ha¨ngt davon
ab, inwieweit es gelingt, den zelltoxischen Effekt auf die Tumorzellen zu begrenzen. Da-
bei spielen sowohl die Wahl geeigneter Photosensibilisatoren als auch die Applikation des
Therapielichts eine Rolle. Mehrere experimentelle und klinische Untersuchungen konnten
zeigen, dass es bei der Verwendung von ALA-induziertem PpIX als Photosensibilisator
zu weniger Nebenwirkungen kommt als bei anderen Sensibilisatoren. Daher scheint dieser
Photosensibilisator in Bezug auf Sicherheitsaspekte besonders interessant fu¨r die Anwen-
dung in der Neurochirurgie zu sein. Die Effizienz des Verfahrens ha¨ngt zum einen von der
Verfu¨gbarkeit von Sauerstoff in den Zellen ab und zum anderen von der Lichtintensita¨t mit
der PPIX angeregt wird. Da es durch Streu- und Absorptionsprozesse im Gewebe zu ei-
ner Da¨mpfung der Lichtintensita¨t kommt, liegt die Eindringtiefe von rotem Therapielicht
nur bei wenigen Millimetern. Dies fu¨hrt dazu, dass die in der Tiefe verfu¨gbare Lichtin-
tensita¨t mit zunehmender Gewebedicke stark abnimmt. Dadurch kommt es insbesondere
bei der oberfla¨chlichen Bestrahlung von massiven Tumoren zu einem Therapieeffekt, der
auf wenige Millimeter begrenzt bleibt. Neue Konzepte zur Applikation des Therapielichts
ko¨nnten den Therapieerfolg der ALA-PDT trotz dieses Pha¨nomens verbessern.
In den vorliegenden Arbeiten werden zwei neu entwickelte Konzepte zur Lichtappli-
kation bei ALA-PDT vorgestellt. Das erste Konzept befasst sich mit der sogenannten
interstitiellen Lichtapplikation. Dabei werden du¨nne radial abstrahlende Lichtapplikato-
ren direkt in einen massiven Tumor eingefu¨hrt und das Therapielicht intratumoral u¨ber
eine La¨nge von einigen Zentimetern abgegeben. Vor der Durchfu¨hrung einer ersten klini-
schen Machbarkeitsstudie wurden in vivo-Messungen optischer Gewebeparameter sowie
optische und thermische Simulationsrechnungen durchgefu¨hrt. Diese Simulationen hatten
zum Ziel, den optimalen Abstand zwischen den einzelnen Fasern und zwischen Fasern
und Tumorrand zu bestimmen. Dabei musste zum einen darauf geachtet werden, dass
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der Abstand nicht zu gering war, da dies mo¨glicherweise zu einer unerwu¨nschten lokalen
Temperaturerho¨hung gefu¨hrt ha¨tte. Zum anderen durfte der Abstand auch nicht zu groß
ausfallen, da sonst die Lichtintensita¨t zwischen den Applikatoren bzw. am Tumorrand zu
gering gewesen wa¨re und man somit die beno¨tigte Photodynamische Dosis nicht erreicht
ha¨tte. Die theoretisch ermittelten Positionen der Lichtapplikatoren konnten mittels einer
modifizierten Software auf die aktuellen CT- und MRT-Bilder der Patienten u¨bertragen
werden. Daraus konnten die exakten Positionen der Applikatoren bestimmt werden und
mittels eines stereotaktischen Verfahrens wurden die Fasern dann entsprechend gesetzt.
Der aus den Simulationen abgeleitete optimale Abstand betrug 9 mm. Es zeigte sich, dass
bei Einhaltung dieser Distanz die Gewebetemperatur nicht u¨ber 42 °C anstieg. Insgesamt
wurden in der so durchgefu¨hrten klinischen Machbarkeitsstudie zehn Patienten behan-
delt. Durch Verwendung von bis zu sechs Applikatoren, die zeitgleich Licht an den Tumor
abgaben, konnten die Tumore aller Patienten komplett bestrahlt werden. Das mittlere
Tumorvolumen betrug 5,9 cm3 und die gesamte abgegebene Bestrahlung betrug zwischen
4320 J und 11529 J. Es konnten keine Nebenwirkungen festgestellt werden. Das mittlere
U¨berleben der Patienten betrug 15 Monate und es gab vier Patienten, die la¨nger lebten
als 24 Monate.
Das zweite Konzept, dass im Rahmen der vorliegenden Arbeit entwickelt wurde, sollte
untersuchen, ob eine Steigerung der Effektivita¨t der ALA-PDT durch Bestrahlung mit
infrarotem Licht erreicht werden kann, da diese Wellenla¨nge eine ho¨here Eindringtiefe in
Gewebe besitzt. Bei Bestrahlung von PPIX mit infrarotem Licht kommt es bei Verwen-
dung von Bestrahlungssta¨rken, wie sie in der PDT u¨blich sind, zwar zu keiner signifikanten
Anregung des Photosensibilisators. Wenn man aber das Anregungslicht bu¨ndelt und PPIX
somit einer erho¨ten Lichtintensita¨t aussetzt, kommt es zu dem nicht-linearen Pha¨nomen
der Zwei-Photonen-Absorption. Dabei wird das Moleku¨hl durch die Absorption zweier
Photonen in einen angeregten Zustand gebracht und kann damit den phototoxischen Pro-
zess in der Zelle in die Wege leiten. Da es sich hierbei um einen sehr experimentellen Ansatz
handelt, konnten Untersuchungen zu dem Konzept nur an Zellen durchgefu¨hrt werden. Bei
den bestrahlten Zellen handelte es sich um Gliomzellen der Ratte (C6). Die Bestrahlung
erfolgte mit gepulstem Laserlicht der Wellenla¨nge 800 nm, das in einem Titan:Saphir-
Laser erzeugt und u¨ber mehrere Optiken gebu¨ndelt wurde. Dadurch konnten die fu¨r den
Zwei-Photonen-Effekt beno¨tigten Lichtintensita¨ten erzeugt werden. Die Zellen wurden
vor der Bestrahlung mit ALA inkubiert. Nach der Behandlung wurde das U¨berleben der
Zellen mit einer Fa¨rbung untersucht (Ethidium-Bromid/Acridin Orange). Nicht inkubier-
te Zellen zeigten einen nekrotischen Effekt bei Bestrahlungssta¨rke > 10,9·1010 W/cm2.
Da diese Zellen nicht inkubiert wurden, ist bei diesen Bestrahlungssta¨rken von einem
thermischen Effekt auszugehen. ALA-inkubierte Zellen zeigten einen nekrotischen Effekt
bereits bei deutlich kleineren Bestrahlungssta¨rken (> 6,1·1010 W/cm2). Da nicht inku-
bierte Zellen bei dieser Bestrahlungssta¨rke keinerlei toxischen Effekt zeigten, ist davon
auszugehen, dass bei den ALA-inkubierten Zellen einen phototoxischer Prozess induziert
werden konnte.
Mit der vorliegenden Arbeit sollten neue Wege der Lichtapplikation bei der ALA-
PDT untersucht werden. Mit der klinischen Umsetzung des Konzepts der interstitiellen
PDT konnte die Sicherheit und Wirksamkeit dieser Methode gezeigt werden. Da das
Konzept der Zwei-Photonen-PDT noch nicht so weit entwickelt ist, konnten hier nur in-
vitro Experimente durchgefu¨hrt werden. Die Weiterentwicklung beider Konzepte ko¨nnte
die PDT als Therapieoption zur Behandlung des Malignen Glioms qualifizieren.
Chapter 1
Introduction
The present doctoral thesis is a cumulative thesis and consists of four original manuscripts
((Stepp et al., 2007), (Beck et al., 2007b), (Stummer et al., 2008), and (Beck et al.,
2007a)). The common objectives of these manuscripts are the investigation of novel light
application concepts for Photodynamic Therapy of malignant gliomas with aminolevulinic
acid induced protoporphyrin IX. Two new concepts were developed and evaluated in
experimental and clinical studies. The description of the concepts and the results of the
studies are published in the above mentioned manuscripts.
Malignant Gliomas
Malignant gliomas are the most common and most malignant primary tumors of the
central nervous system (CNS). Gliomas arise from glial cells and are classified by a four
point scale of the World Health Organization (WHO) depending on the histologic grade
of the tumor as determined by pathologic evaluation (Louis et al., 2007). WHO grade
I and II are low grade tumors, which are well-differentiated, slowly growing, biologically
less aggressive, with a good prognosis for the patient. WHO grade III and IV are high-
grade gliomas (malignant gliomas), which are undifferentiated or anaplastic, fast growing,
invading adjacent tissues, and carrying a poor prognosis. Malignant gliomas are highly
vascular tumors and have a tendency to infiltrate. They have extensive volumes of necrosis
and hypoxia. Often tumor growth causes a breakdown of the blood-brain barrier in the
vicinity of the tumor. High-grade gliomas almost always recur even after complete surgical
excision.
Another classification of gliomas can be done according to the specific type of cell
they most resemble. Ependymomas derive from ependymal cells and emerge in grade
II and III. Oligodendrogliomas derive from oligodendrocytes and occur in grade II and
III. Astrocytomas are the most common gliomas and derive from astrocytes cells of the
brain. This glioma type can be found in all four grades: Pilocytic astrocytoma (grade
I), diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III), and glioblastoma
multiforme (grade IV). Finally, mixed gliomas occur, such as oligoastrocytoma, which is
a combination of astrocytomas and oligodendrocytes.
In Germany, the number of newly diagnosed primary intracranial tumors is about
8,000 per year (Hirntumorhilfe, 2009). More than 70% of all primary brain tumors are
gliomas (Ohgaki, 2009). About half of all gliomas are glioblastoma multiforme (GBM).
GBM occurs at 2-3 cases per 100,000 people in Germany and is the most common and
aggressive type of primary brain tumor. Most patients are between 50 and 70 years old
and about 1/3 is female and 2/3 is male.
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Diagnosis and Therapy
The overall prognosis for patients suffering from a malignant glioma continues to be dis-
mal. The median survival of patients suffering from a glioblastoma multiforme (WHO
grade IV) after tumor resection, external beam irradiation, and various forms of chemother-
apy still lies in the range of 12-14 months (Shapiro et al., 1989; Jemal et al., 2004; Stupp
et al., 2009).
Two reviews about diagnosis and treatment of high-grade astrocytomas (Sathorn-
sumetee et al., 2007) and recurrent high-grade astrocytomas (Butowski et al., 2006) have
been published lately. Diagnosis is mostly performed with modern imaging techniques
such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI) (Cha, 2004),
Magnetic Resonance Spectroscopy (MRS) (Meyerand et al., 1999), and Positron Emis-
sion Tomography (PET)(Chao et al., 2001; Rachinger et al., 2005). These techniques
are well established and associated with minimal side effects. The most accurate diag-
nosis, however, requires histopathological investigation of excised tissue, taken either as
a stereotactic biopsy or during tumor resection, since tumor grading can be determined
only histologically.
There are several approaches to treat malignant gliomas. Generally, tumor resection
is performed as a first therapeutic measure. The strategy to reduce tumor mass seems to
have a benefit to patient’s survival, as could be shown by retrospective analysis of residual
tumor after resection and its influence on prognosis (Albert et al., 1994; Lacroix et al.,
2001). Stummer et al. could show by analysis of postoperative MRI findings, that patients
without residual contrast-enhancing tumor had higher overall median survival than those
with residual-enhancing tumor (17.9 months vs. 12.9 months) (Stummer et al., 2006).
Decreasing tumor mass seems therefore to be helpful in order to improve the efficacy
of adjuvant therapies. One of the results of a study investigating the effectiveness of
temozolomid seems to confirm this approch, since patients with a complete tumor had
showed a better therapeutic outcome after radiochemotherapy with temozolomid (den
Bent et al., 2006).
Although a complete resection seems to be advantageous, the radicality of resection
has its limits due to tumor locations close to eloquent areas (Albert et al., 1994). A widely
used concomitant therapy is radiation therapy, which can be performed with several tech-
niques. Clinical trials have been performed for conventional radiotherapy (Veninga et al.,
2001), intensity-modulated radiotherapy (IMRT) (Voynov et al., 2002), temporary (Sneed
et al., 1997) or permanent (Gaspar et al., 1999) brachytherapy, single- or multifraction
radiosurgery (Hall et al., 1995; Cho et al., 1999).
Until some years ago, chemotherapy as a further treatment approach had limited ther-
apeutic outcome when malignant gliomas were treated, which may be associated with the
blood-brain-barrier. However, some years ago, a trial of the European Organisation for
Research and Treatment of Cancer could show that treating malignant gliomas with a
combination of surgery, radiotherapy, and chemotherapy seems to be a promising ap-
proach (Stupp et al., 2005; Hegi et al., 2005). One of the findings of this study was that
overall survival was 2 months higher with concomitant adjuvant radiochemotherapy with
temozolomide followed by adjuvant temozolomide than with radiotherapy alone.
Besides all these efforts, median survival of patients suffering from malignant gliomas
is still restricted to 15 months. Tumor recurrences usually occur locally at the margin
of previously treated tumor volumes (Bashir et al., 1988; Albert et al., 1994). Thus, the
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spectives in the treatment of brain tumors. One of these concepts could be Photodynamic
Therapy (PDT) and its principle and clinical applications are discussed in the following.
Basic Principle of Photodynamic Therapy
Photodynamic therapy (PDT) is a light activated therapy and its basics have been discov-
ered about 100 years ago. In 1898, the medical student Oscar Raab performed cell culture
experiments in order to investigate potential anti-malarial agents and found that certain
substances increased their toxicity when illuminated with light (Raab, 1898). Some years
later, in 1903, Hermann von Tappeiner and Albert Jesionek implemented this ’light ef-
fective’ phenomenon to the clinic and treated the first patient suffering from skin cancer
(v. Tappeiner and Jesionek, 1903). From then on, further research was performed and
several clinical applications of the new form of therapy were investigated, but the clinical
outcome was limited. Until, due to advances in the development of the light absorbing
molecules, also called photosensitizer, PDT started its comeback about 40 years ago.
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Figure 1.1: Energy level for a photosensitizer activated by red light.
The toxicity of the photodynamic effect is based on the interaction of light with the
photosensitizer located in the target tissue. The photosensitizer is excited from a ground
singlet state to an excited singlet state. It then undergoes intersystem crossing to a
longer-lived triplet state. When the photosensitizer and an intracellular oxygen molecule
are in proximity, an energy transfer can take place that allows the photosensitizer to
relax to its ground singlet state, and create an excited singlet state oxygen molecule (see
Fig. 1.1). Singlet oxygen is a very aggressive chemical species and will very rapidly react
with any nearby biomolecules. Ultimately, these destructive reactions will result in cell
killing through apoptosis or necrosis.
At first glance, the need of the three components oxygen, photosensitizer, and light
seems to make this therapy concept complicated. However, this complex system offers
also the perspective to limit the toxic effect to a target volume or area, which could be
advantageous regarding safety aspects of a new therapy. This selectivity can in principle
be obtained either by a selective accumulation of the photosensitizer or by applying the
therapeutic light only to selected tissue regions. Both, a highly selective photosensitizer
and a selective light application are discussed below.
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Due to this promising properties, photodynamic therapy (PDT) has received increased
attention as a treatment modality for tumors and other diseases in several clinical areas,
e.g. dermatology, urology, ophthalmology, and otorhinolaryngology. In neurosurgery,
PDT was implemented as a new treatment modality some decades ago.
Photodynamic Therapy in Neurosurgery
The treatment of recurrent glioblastomas with PDT was reported for the first time by
Perria in 1980 (Perria et al., 1980) after Diamond had suggested in 1972 the use of PDT
for the treatment of brain tumors (Diamond et al., 1972). Since then, many small clinical
trials were performed to investigate the safety and efficacy of this treatment modality.
Mostly, the photosensitizers used were porphyrin based such as hematoporphyrin deriva-
tive (HpD), a mixture of ether and ester linked porphyrins, or its purified forms Photofrinr
(porfimer sodium) and Photofrin IIr (dihematoporphyrin ether/ester). A review has been
published by Madsen and Hirschberg (Madsen and Hirschberg, 2006).
The technical and clinical setups of the studies were various. However, most studies
applied PDT as adjuvant therapy after tumor resection and light irradiation was done
intracavitarily. One approach was to place a balloon device within the resection cavity
as light source. Muller and Wilson treated recurrent (Muller and Wilson, 1995) and
newly diagnosed (Muller and Wilson, 1996) supratentorial gliomas by inserting a balloon
irradiator (described in (Wilson et al., 1986)) into the resection cavity and expanded
it with a light dispersion medium. Other groups used the same or a modified balloon
applicator to treat recurrent brain tumors after resection (Origitano and Reichman, 1993;
Schmidt et al., 2004) or suggested to implant a permanent balloon catheter, which could
help to perform a long term photodynamic therapy (Madsen et al., 2001).
Another approach to illuminate the resection cavity is to position a simple light guid-
ing fiber in the center of the cavity (Perria et al., 1980; Kostron et al., 1996; Rosenthal
et al., 2001; Stylli et al., 2005). Usually, the illumination involves the use of a light
dispersing medium which is placed within the resection cavity in order to uniformly dis-
tribute the light within the resected tumor cavity (Stylli and Kaye, 2006). The influence
of a scattering medium on the light distribution of the surface was investigated for hollow
organs (Star et al., 1987; Beyer, 2003). From these studies it can be deduced, that when
the geometry of the resection cavity deviates from the ideal shape of a sphere or when
the position of the light guiding fiber is not in the center of the sphere, then the use of a
scattering medium results in a less homogeneous light distribution on the tissue surface
compared to the use of a transparent medium. Thus, using a light-scattering medium is
not of advantage to achieve a uniform light distribution across the entire surface.
For deep seated or non-resectable tumors a possibly minimally invasive way to ap-
ply the light to the sensitized tumor is to place light guiding fibers directly within the
treatment volume. This treatment modality is referred to as interstitial photodynamic
therapy (iPDT). Its feasibility and effectiveness has been investigated in brain tumor
models (Cheng et al., 1984; Lilge et al., 1996; Hebeda et al., 1998a) and in first clinical
applications with HpD (E. R. Laws et al., 1981; Lajat and Patrice, 1987) and Photofrin
or Photofrin II (Powers et al., 1991; Origitano and Reichman, 1993; Kaneko, 1999; Kr-
ishnamurthy et al., 2000; Schmidt et al., 2004).
Some of these studies have shown that Photofrin-mediated PDT may prolong survival
(Muller and Wilson, 1987; Muller and Wilson, 1996). Despite, PDT is not included in the
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to the lack of proof of efficacy by prospective, randomized clinical trials. The other reason
may be due to the severe treatment related adverse effects reported by several authors.
The use of hematoporphyrin derivative and Photofrin leads to a photosensitization also
of the skin, which forces patients to avoid direct or diffuse sun light for about 2 months
(Muller and Wilson, 1996; Popovic et al., 1996). An even more severe side effect is the
unspecific damage to normal brain tissue associated with the therapy. It seems that there
is a leakage across the blood-brain barrier within malignant glioma, which leads to an
unspecific sensitization of peritumoral tissue due to transport of the photosensitizer with
edema bulk flow (Dereski et al., 1989; Stummer et al., 1993; Chen et al., 1996; Stummer
et al., 1996; Goetz et al., 2002).
All these experiences lead to the assumption, that a photosensitizer, which would
accumulate more selectively in tumor tissue could reduce side effects associated with PDT
treatment. Aminolevulinic acid induced protoporphyrin IX seem to be such a tumor
selective photosensitizer and could have the potential to reanimate PDT as a therapy
modality in neurosurgery.
ALA-based PDT
In most photosensitizing drugs, which have obtained regulatory approval in the last years,
e.g. Photofrin, Visudyne, Foscan, the photosensitizer, i.e. the light absorbing molecule,
is applied directly to the patient. In contrast to this, in ALA-PDT, the photosensitizer
protoporphyrin IX (PpIX) is not applied directly, but the precursor aminolevulinic acid
(ALA) is given and PpIX is synthesized in situ from ALA. ALA is naturally occurring
in cells as part of the heme synthesis. The synthesis of endogenous ALA is controlled by
the presence of unused heme via a feedback mechanism. The administration of exoge-
nous ALA bypasses the rate-limiting step in the synthesis of heme and every step in the
biosynthetic pathway tries to operate at its maximum capacity. Since PpIX is the direct
precursor of heme, a cell, in which the rate of PpIX synthesis is greater than the rate
of its conversion into heme, accumulates PpIX. This mechanism of PpIX accumulation
is illustrated in Fig. 1.2. Usually, malignant tissue accumulates significantly more PpIX
compared to normal tissue of similar origin, which can lead to a high tumor selectivity of
ALA-PDT. The activities of two enzymes in the heme biosynthetic pathway play a major
role in PpIX generation and accumulation: ferrochelatase (FC) is responsibe for the con-
version of PpIX into heme and porphobilinogen deaminase(PBGD), which is responsible
for the synthesis of the precursor uroporphyrinogen.
PpIX is produced primarily in the mitochondria, but can be redistributed into the
cytosol and perinuclear region after longer incubation times. The action radius of gener-
ated singlet oxygen is only about 10-20 nm. Cell death can be caused either by apoptotic
or necrotic pathway. Apoptosis is a physiological and controlled cell death. Necrosis is a
passive cell death, mainly caused by plasma membrane destruction.
Beyond these direct phototoxic effects, activation of the immune response after PDT
has been reported (e.g. increased expression of heat shock proteins) (van Duijnhoven
et al., 2003; Jalili et al., 2004; Korbelik et al., 2005). These effects are under ongoing
experimental investigation and clinical evaluation.
Many clinical applications using ALA-PDT were investigated in the last years (Pottier
et al., 2006).
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Figure 1.2: Protoporphyrin IX is produced during the heme biosynthesis.
ALA in Neurosurgery
Several experimental studies examining the usability of ALA as a fluorescence marker in
brain tumor models have been performed in the last 10 years (Stummer et al., 1998b;
Hebeda et al., 1998b; Tsai et al., 1999). The results encouraged Stummer et al. to use
ALA for the first time in patients and they found a highly selective tumor uptake and only
minimal skin sensitization (Stummer et al., 1998c; Stummer et al., 1998a; Stummer et al.,
2000; Stummer et al., 2003). A prospectively-randomized phase III study investigated
the usefulness of fluorescence-guided surgery with ALA from 1999 to 2004 (Stummer
et al., 2006) and resulted in the European approval of aminolevulinic acid (generic name:
Gliolan®) with the indication of intraoperative photodynamic diagnosis of residual glioma
(Krammer and Plaetzer, 2008). Fig. 1.3 shows the impressive tumor demarcation of a
malignant glioma under fluorescence excitation light.
The successful establishment of ALA in the intraoperative diagnosis of malignant
gliomas is due to a high tumor selectivity of the photosensitizer accumulation. Mainly,
this effect can be ascribed to the fact, that the synthesis and accumulation of PpIX
occurs directly within the tumor cells in contrast to HpD and Photofrin. However, a
key prerequisite for PpIX accumulation in brain tumors is a disruption in the blood-
brain barrier, since ALA is a polar molecule and could not pass an intact blood-brain
barrier (Novotny et al., 2000; Ennis et al., 2003). Additionally, it is presumed that tumor
proliferation plays another important role for the intratumoral PpIX synthesis (Novotny
et al., 2000).
As described before, such tumor selective properties are one of the prerequisites of
a safe photodynamic tumor therapy and thus, one would expect ALA-PpIX to be a
potential and safe photosensitizer for PDT. Therefore, the potential of ALA-PpIX as a
PS for PDT of malignant gliomas has been investigated in several experimental studies in
vitro (Madsen et al., 2000; Hirschberg et al., 2002; Madsen et al., 2003; Hirschberg et al.,
2006; Zelenkov et al., 2007; Inoue et al., 2007; Madsen et al., 2009) and in vivo (Olzowy
7et al., 2002; Hirschberg et al., 2002; Angell-Petersen et al., 2006; Madsen et al., 2006).
Both, the in vitro and the in vivo studies were very promising and it seemed that using
ALA induced PpIX as a tumor selective photosensitizer could solve the safety problem,
which occurred when using other sensitizers. These results encouraged the first clinical
ALA-PDT studies in the brain. In 2001, Hochstetter (Hochstetter, 2001) treated the
first patients suffering from glioblastoma. In this preliminary investigation, 5 patients
received ALA prior to surgery. After tumor resection, PpIX fluorescence was detected
and the tumor cavity was irradiated with a cylindrical diffuser. No side-effects were
observed and MR images showed an effective zone of 2 cm diameter without sign of brain
edema.
Based on these promising results, in 2002 a multi-center study started at the De-
partments of Neurosurgery in Munich and Dusseldorf, Germany. The aim was to apply
ALA-PDT as an adjuvant therapy after tumor resection. The experiences obtained dur-
ing this trial were partly published by Stepp et al. (Stepp et al., 2007). The study could
show the safety and effectiveness of this therapy.
The contribution of Tobias J. Beck to this study was to implement the
irradiation in the clinic, to measure the fluorescence of the photosensitizer
before, during and after the irradiation, to analyze the fluorescence spectra,
and to determine the photobleaching effect.
Figure 1.3: Image of a malignant glioma through an operation microscope under white
light illumination (left image) and under illumination with fluorescence excitation light
(right image).
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Novel irradiation concept I
As discussed above, there is still a limited effectiveness of ALA-PDT. One of the reasons
seems to be a limited light intensity within the target tissue. When irradiating the surface
of the tumor, the light intensity decreases rapidly in deeper tissue layers, which is mainly
due to light scattering and absorption. Therefore, the objective of the present work
was to develop and evaluate novel concepts of light application in order to increase the
effectiveness of ALA-PDT as a treatment modality for malignant gliomas.
Within the first concept, the tumor was supposed to be irradiated from inside, instead
of illuminating the tumor surface. This therapy concept has been referred to as interstitial
Photodynamic Therapy (iPDT). The study focused on the development and the clinical
implementation of an accurate and reproducible irradiation scheme for iPDT with the
aim to overcome the limited penetration depth of therapeutic light and to illuminate the
entire bulk tumor. In order to obtain an effective and homogeneous therapeutic effect
within the treatment volume, it is important to know the light distribution within the
tissue. This light distribution is determined by the interaction of photons with tissue
structures. Monte Carlo simulations of fluence rate and heat transport simulations were
performed using the optical properties of normal brain tissue infiltrated by tumor cells.
The optimum distance between the inserted light diffusers was determined to be 9 mm
with regard to both fluence rate and temperature distribution. For this distance a tem-
perature increase above 42 °C was not expected to occur. For the clinical implementation
of the simulated data, a modified 3D-treatment-planning software was used to calculate
both, the treatment-volume and the exact position of the light diffusers within the lesion.
Up to six cylindrical light diffusers were stereotactically implanted to achieve a complete
irradiation of the tumor volume, which was possible in every single patient. The feasibility
and the risk of iPDT were tested in 10 patients with small and circumscribed recurrent
malignant gliomas. Side effects of iPDT were not observed during the study and the me-
dian survival was 15 months. The technical setup and the first clinical results of the iPDT
study were published by Beck et al. (Beck et al., 2007b). Stummer et al. published a
case report of one patient treated with iPDT, which focused on the clinical impact of this
treatment modality (Stummer et al., 2008). The patient suffered from a prior left frontal
glioblastoma multiforme treated by surgery, radiation and chemotherapy, and developed
a remote lesion in the left insula, which was refractory to secondary treatments. After
treating the patient as described above, the contrast uptake in the lesion had disappeared
in the MRI images 24 h after therapy. Circumferential contrast enhancement was ob-
served at 72 h, which disappeared in the course of subsequential months. Edema resolved
completely. The patient was free of recurrence 56 months after treatment.
The contribution of Tobias J. Beck to these two manuscripts was to in-
vestigate the basics of light application with optical and thermal simulations,
modeling the light distribution within the irradiated tissue, helping to imple-
ment the theoretical data in the clinical setup, developing technical equipment
used for the treatment, supporting the stereotactical procedure, and preparing
the manuscript (Beck et al., 2007b) together with Prof. Kreth.
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The other concept investigated the usability of another type of light source in order
to induce the phototoxic effect in ALA-incubated cells: infrared (IR) laser light, which
in general has a higher penetration depth compared to red light. Unfortunately, light
intensities usually used in red light PDT (200 mW/cm2) are not effective at all when
irradiating with IR light, since PpIX does not absorb light within this wavelength region
very effectively. However, when PpIX is exposed to very high light intensities of IR light,
then there is a chance to induce a PDT effect by exciting the sensitizer via two-photon
absorption. In this process an atom or molecule absorbs two photons at approximately
the same time and achieves an excited state that corresponds to the sum of the energy
of the incident photons (see Fig. 1.4). There need not be an intermediate state for the
molecule to reach before arriving at the final excited state. Instead, the atom is excited
to a ”virtual state” which need not correspond to any electronic or vibrational energy
eigenstate. The theory of this phenomena was first developed by Go¨ppert-Meyer in 1931
(Go¨ppert-Mayer, 1931). In 1961, the first lasers came up and the theory could be verified
with experiments.
The resulting excited state after two-photon excitation (TPE) offers an identical be-
havior compared to molecules undergoing an ordinary single photon absorption. Thus,
TPE excited molecules can also relax by emitting fluorescent light or by interacting with
oxygen resulting in reactive oxygen species.
λ  =  400 nm λ  =  800 nm
Figure 1.4: Term scheme for single photon excitation (SPE) and for two photon excita-
tion (TPE).
The effect of two-photon or multiphoton excitation has already found diagnostic appli-
cations in life science: near infrared (NIR) multiphoton microscopy is a novel optical tool
for fluorescence imaging based on non-resonant two-photon fluorophore excitation (Ko¨nig,
2000). This technique allows to obtain morphological and functional fluorescence images
of endogenous fluorophores. However, also exogenous fluorophores can be imaged with
high spatial resolution. Madsen et al. (Madsen et al., 2000) reported about two-photon
fluorescence microscopy in human glioma spheroids in order to show the conversion of
5-ALA to PpIX throughout the entire spheroid volume.
Besides fluorescence effects, two-photon excited PDT has also gained interest, mainly
due to the expected higher therapeutic penetration depth in tissue compared to VIS-
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single-photon excitation. In addition to the higher penetration depth, the two-photon
photodynamic therapy has the potential of improving the therapeutic outcome due to a
highly localized photodynamic effect, since the tissue volume, where the light intensity is
high enough, is only some µm3.
About ten years ago, first experimental studies were published (Fisher et al., 1997;
Bhawalkar et al., 1997). Since then, reports have been published investigating basic path-
ways of TPE (Goyan and Cramb, 2000; Frederiksen et al., 2001; Dittrich and Schwille,
2001; Frederiksen et al., 2005; Samkoe et al., 2006), how to enhance two-photon absorp-
tion by using novel effective two-photon phototherapeutic agents (Drobizhev et al., 2002;
Liu et al., 2002; Ogawa et al., 2006), and about the treatment of cells in vitro (Ko¨nig et al.,
1999; Karotki et al., 2006). Furthermore, the application of TPE-PDT in clinical thera-
pies, such as treatment of age-related macular degeneration (AMD), were investigated in
model systems (Samkoe and Cramb, 2003).
Novel irradiation concept II
The approach of the present study was to investigate TPE-PDT in cell culture exper-
iments. Monolayers of C6 rat glioma cells were irradiated with a pulsed and focused
fs Ti:Sapphire laser emitting light at 800 nm. The beam profile of the laser beam was
carefully analyzed before the experiment and the applied irradiance was known for each
position within the irradiated cell layer. Cells were divided into four groups, three control
groups (no drug and no light, drug but no light, light but no drug) and one group, that
was incubated with 5-ALA and irradiated 4 to 5 hours later. The survival of this group
was tested after irradiation by means of ethidium bromide and acridine orange staining
and compared to a control group, which was irradiated under the same conditions, but
not incubated with 5-ALA before. Both groups showed necrotic areas depending on the
applied irradiance. Cells of both groups became necrotic when treated with an irradiance
above 10.9 · 1010 W/cm2. 5-ALA incubated cells became necrotic also after irradiation
with a mean irradiance down to 6.1 · 1010 W/cm2, while non-incubated cells remained
viable below 10.9 · 1010 W/cm2. Therefore it seemed, that below a mean power density
of 10.9 · 1010 W/cm2 no thermal damage was induced in the cells and necrosis of the
5-ALA incubated cells can be ascribed to the photodynamic effect induced by two-photon
excitation. The results of this experimental study were published by Beck et al. (Beck
et al., 2007a).
The contribution of Tobias J. Beck to this study was to measure and cal-
culate the applied light intensities, modeling the light distribution within the
monolayer of cells, performing the light irradiation, evaluating the data of the
area of necrotic cells, measuring the PpIX fluorescence of the incubated cells
before the treatment and preparing the manuscript.
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Background and Objective: Limited knowledge of the
light and temperature distribution within the target
volume in combination with non-selective accumulation of
the applied photosensitizers (PS) has hampered the clinical
relevance of interstitial photodynamic therapy (iPDT) for
treatment of malignant glioma patients. The current pilot
study focused on the development and the clinical imple-
mentation of an accurate and reproducible irradiation
scheme for iPDT using 5-aminolevulinic acid (5-ALA)
induced protoporphyrin IX (PPIX) as a selectively working
PS.
Study Design/Materials and Methods: Monte Carlo
simulations of fluence rate and heat transport simulations
were performed using the optical properties of normal brain
tissue infiltrated by tumor cells (absorption coefficient
ma¼ 0.2 cm1, reduced scattering coefficient: m0s¼ 20 cm1).
A modified 3-D treatment-planning software was used to
calculate both, the treatment-volume and the exact posi-
tion of the light diffusers within the lesion. The feasibility
and the risk of iPDT were tested in 10 patients with small
and circumscribed recurrent malignant gliomas.
Results: The optimum distance between the implanted
light diffusers was determined to be 9 mm with regard to
both fluence rate and temperature distribution. For this
distance a temperature increase above 428C was not
expected to occur. Up to six cylindrical light diffusers were
stereotactically implanted to achieve a complete irradiation
of the tumor volume, which was possible in every single
patient (mean tumor volume: 5.9 cm3). The total applied
light fluence was between 4,320 J and 11,520 J. Side
effectsof iPDT were not observed. Median survival was
15 months.
Conclusion: 5-ALA iPDT in combination with a 3-D
treatment-planning (which was based on optical and
thermal simulations) is a safe and feasible treatment
modality. The clinical impact of these findings deserves
further prospective evaluation. Lasers Surg. Med. 39:386–
393, 2007.  2007 Wiley-Liss, Inc.
Key words: neurosurgery; photodynamic therapy;
stereotactic; interstitial; intratumoral; light application;
brain tumor; glioblastoma; 5-aminolevulinic acid; proto-
porphyrin IX; cylindrical diffuser; dosimetry
INTRODUCTION
Glioblastoma multiforme is the most common and most
malignant primary brain tumor in humans and the overall
prognosis for patients continues to be dismal. The median
survival after tumor resection, external beam irradiation,
and various forms of chemotherapy still lies in the range of
12 months [1,2]. Taken into account that tumor recurrences
usuallyoccur locallyat themarginofpreviously treated tumor
volumes [3,4], the improvement and further development of
local treatmentconceptssuchasphotodynamictherapy(PDT)
remains a matter of utmost importance [5–10].
Treatment effects of PDT are based on the accumulation
of photosensitizing drugs (PS) in malignant tissue, which
exert tumor-toxic properties after activation by light of
an appropriate wavelength. A possibly minimally invasive
way to apply the light to the sensitized tumor is to place
light guiding fibers directly within the treatment volume.
This treatment modality is referred to as interstitial
photodynamic therapy (iPDT). Its feasibility and effective-
ness has been investigated in brain tumor models [11,12]
and in first clinical applications with Photofrin [13–16].
Unfortunately, prolonged skin sensitization and damage to
normal brain tissue due to the limited selectivity of the
applied PS (Photofrin or Photofrin II) have obstructed the
broad application of this potentially minimal invasive
treatment concept.
5-aminolevulinic acid (5-ALA) induced protoporphyrin
IX (PPIX) has proven its high potential as a PS for PDT in
several experimental studies [17–20] and has recently
gained interest in neurosurgery [21,22] due to a selective
tumor uptake and only minimal skin sensitization [23–25].
The current pilot study focused on the development
of an accurate and reproducible irradiation scheme for the
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5-ALA iPDT approach (e.g. optimal intratumoral fiber
positioning and interfiber distance, applied fluence, fluence
rate, and temperature distribution) and the feasibility of its
clinical implementation. It was hypothesized that state
of the art stereotactic techniques enabling both a 3-D-
dosimetry and the optimal placement of the light guiding
fibers in combination with a highly tumor selective PS such
as 5-ALA induced PPIX would lead to controlled treatment
effects and a significant reduction of the risk of the therapy.
The feasibility and the risk of iPDT was analyzed in 10
patients with a circumscribed recurrence of a malignant
glioma with a maximum diameter of 3 cm. The study
protocol was approved by the institutional review board of
the Ludwig-Maximilians-University, Klinikum Grossha-
dern, Munich.
MATERIALS AND METHODS
Technical Setup
The illumination was performed using a laser, a beam
splitter, and light diffusers. The light source was a diode
laser emitting light at a wavelength of l¼ 633 nm with a
maximum output power of 4 W (Ceralas PDT Diode Laser,
biolitec AG, Jena, Germany). The laser light was coupled
via a 400 mm fiber and a lens into a beam splitter with a
variable number of output ports and variable output
powers for each port. Up to six diffusers with variable
diffuser lengths could be illuminated simultaneously with a
constant power of 200 mW/cm.
Fiber-based cylindrical light diffusers were used as
treatment fibers (CD403, CeramOptec GmbH, Bonn,
Germany). The diffuser tips had an outer diameter of
d¼ 1.6 mm and a radiation length of l¼ 20 mm or l¼ 30 mm
(CD403-20 and CD403-30, respectively, Fig. 1). Depending
on the tumor geometry, the 20 mm or 30 mm diffusers were
used. The spatial light distribution of both diffuser lengths
used is given in Figure 1. The light intensity distribution
measured along the radiating zone was nearly homoge-
neous. X-ray markers on both ends of the radiating zone
enable an X-ray controlled positioning.
Determination of the Irradiation Scheme
Pre-operatively, the temperature distribution was calcu-
lated with a commercial Monte Carlo-based simulation
program using interfiber distances between 7 and 9 mm
(LITCIT 32, LMTB GmbH, Berlin, Germany) [26]. In the
LITCIT simulations, four cylindrical light diffusers were
positioned at the edges of a square. The light power emitted
from the diffusers was set to 200 mW/cm diffuser length,
which had been already used for iPDT of malignant
glioma by Powers et al. [13]. Optical tissue parameters for
glioblastoma recurrences were not available. Instead, the
optical properties of normal brain tissue infiltrated by
tumor cells (BAT) were used [27], as a model for a
multimodally treated malignant glioma. These parameters
are similar to in-vivo measurements performed by Muller
and Wilson [28,29]. The absorption coefficient ma was set to
0.2 cm1 and the reduced scattering coefficient m0s to
20 cm1, resulting in an optical penetration depth (deff) of
3 mm (deff¼ (3ma(maþm0s))1/2). The relevant heat transport
parameters were set as follows: initial tissue temperature:
37C, blood perfusion: 0.5 ml/(g minute), water content:
75%, heat conductivity: 0.0048 W/(cm K), heat capacity:
3.4882 J/(g K), density: 1.075 g/cm3 [26].
The fluence rate distribution was calculated with Monte
Carlo simulations based on the algorithm of Prahl [30],
using the optical parameters of BAT. Results were obtained
by simulating 1,000,000 histories with a running time of
some 30 minutes on an Intel Pentium M at 1400 MHz with
512 MB RAM. The fluence rate levels were simulated for
one single diffuser. The fluence rate distribution in between
two or more fibers could be deduced from these results by
summing up the contributions of each single fiber.
Light Fluence
The threshold light fluence necessary to induce a
significant phototoxic effect in malignant glioma tissue
has still not been defined for the 5-ALA-iPDT approach.
Clinical protocols for surface irradiation with 5-ALA-PDT
usually operate with fluences in the range of 100 J/cm2.
Excessive photobleaching of the PS occurs at this fluence,
and further irradiation should not be associated with a
significant increase of phototoxicity. Therefore, the irradia-
tion time was only limited with respect to the duration and
invasiveness of the surgical procedure; side effects due to an
excessive fluence were not expected. One hour was consi-
dered an appropriate irradiation time. The resulting total
fluence and the fluence per tumor volume were calculated
with the light power of 200 mW/cm diffuser length.
Patient Selection
Adult patients with a circumscribed recurrence of a
malignant glioma with a maximum diameter of 3 cm (as
defined by gadolinium enhanced T1 weighted magnetic
Fig. 1. Top: Cross section of the applicator CD403-20 including
X-ray marker at the distal end. Bottom: Radiation profile of the
two applicator types, l¼ 20 mm (—) and l¼ 30 mm (- - -).
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resonance imaging (MRI)) and a Karnofsky Score (KPS) of at
least 70 were considered eligible for the study. A confirma-
tory stereotactic biopsy was required for all patients.
Stereotactic Treatment Planning
Treatment planning was based on multimodal imaging
data: image fusion of the stereotactically localized compu-
terized tomography (CT) scans (contrast enhanced scans, 2
mm slices), with additional MRI (T1 weighted gadolinium
enhanced scans, 1 mm slices, T2-weighted scans, 2 mm
slices), and FET-PET (O-(2-[18F]fluoroethyl)-L-tyrosine—
positron emission tomography) scans were done for optimal
visualization of the tumor and exact definition of the
treatment volume (Image Fusion Software, BrainLAB AG,
Heimstetten, Germany).
Irradiation planning was performed with the @target
1.19 software (BrainLAB AG). This program was originally
designed for the planning of stereotactic biopsy trajectories
and Iodine-125 seed implantation. An additional feature is
the 3-D tumor demarcation and calculation of the tumor
volume. It supports also the placement of treatment
catheters within the tumor under full 3-D control of their
position within the brain.
Stereotactic Surgery
One hour prior tosurgery, patientsreceived 20mg/kgbody
weight 5-ALA (medac GmbH, Wedel, Germany) dissolved in
100 ml water orally. This dose is well tolerated and
associated with strong fluorescence in malignant glioma
[24]. All patients were treated under general anesthesia.
Intraoperatively, the oxygen saturation was set to 100% in
order to prevent a possible lack of cellular oxygen due to
oxygen consumption during the treatment [31,32].
The output power of each diffuser was controlled with an
integrating sphere. All fibers had an X-ray marker and the
accuracy of the stereotactic implantation procedure was
checked online during the operation with an orthogonal X-
ray technique using a C-arm. The inserted fibers were fixed
at the entry point with a fiber clip to avoid displacement.
Patient Evaluation
The first postoperative MRI investigation (T1/T2, with/
without gadolinium) was done at day one after surgery for
assessment of early treatment effects. Further clinical and
neuroradiological follow-up was performed 1 month post-
operatively and from then on at 3-month intervals at the
outpatient clinic. Length of survival was calculated with
the Kaplan–Meier-method.
RESULTS
Irradiation Scheme
Heat transport simulations were performed using inter-
fiber distances between 7 and 9 mm. At an interfiber
distance of 7 mm the temperature in the vicinity of a
diffuser increased up to 428C, whereas an interfiber
distance of 9 mm resulted in a maximum temperature in
the range of 418C (Fig. 2). For this distance, further
simulations with unfavorable parameter combinations
(variations of absorption and scattering coefficients and
heat transport parameters of up to 20%) were performed
and did not result in a temperature increase above 428C.
Therefore, a distance of 9 mm seems to be sufficient in order
to prevent unfavorable temperature increase within the
irradiated tissue. Thus, further treatment planning was
based on this interfiber distance.
The fluence rate levels around a single diffuser were
calculated with a Monte Carlo program. Figure 3 shows the
resulting iso-fluence rates when the applicator has a diffuser
length of 2 cm and emits 200 mW/cm. The fluence rate at a
distance of 4.5 mm from the applicator’s surface is 260 mW/
cm2. Thus, in between two diffusers at an interfiber distance
Fig. 2. Temperature distribution within the irradiated tissue according to LITCIT simula-
tions at an interfiber distance of 7 mm (left) and 9 mm (right).
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of 9 mm, the fluence rates of both diffusers add to a total
fluence rate of 520 mW/cm2. This value was set to be the
threshold value, which should also be obtained at the tumor
margin, where, to a first approximation, only one light
diffuser illuminates the tissue. As can be seen in Figure 3,
520 mW/cm2 is obtained at a distance of about 3 mm from the
applicator’s surface. Accordingly, 3-D treatment planning is
based on the maximum distance between the applicator’s
surface and the tumormargin. Due to the fast decrease of the
fluence rate with increasing distance from the light diffuser
(Fig. 3), an approximately 1.5 mm increased distance from
the tumor border or interfiber distance reduces the available
fluence rate by a factor of 2.
As the irradiation time was set to be 1 hour (as described
above), a minimum fluence of 1,870 J/cm2 was obtained at
the tumor margin and in between the two diffusers. The
light fluence per diffuser length was 720 J/cm. Irradiation
parameters are listed in Table 1. The total applied light
fluence depended on the number and length of the inserted
light diffusers and was between 4,320 J and 11,520 J (mean:
7,212 J).
Treatment Implementation
The irradiation volume was estimated and visualized
using the @target 1.19 software: A cylindrical irradiation
volume with a diameter of 7.6 mm (radial distance from
diffuser surface: 3 mm; diffuser diameter: 1.6 mm) was
generated around each diffuser used and the corresponding
iso-fluence was displayed in axial, sagittal, and coronar
projections. It was aimed to overlap the entire treatment
volume with these treatment cylinders. Taken into account
the calculated optimal inter-fiber distance of 9 mm, only a
minimal overlapping of the cylindrical irradiation volumes
was allowed. Special care was taken that the stereotacti-
cally defined trajectories for fiber implantation run parallel
to each other. In case of a complete irradiation of the
treatment volume it could be expected that the fluence rate
exceeded 520 mW/cm2. A typical screen shot of the 3-D
planning program is shown in Figure 4.
Feasibility and Risk of iPDT
During a 1-year period (October 2002–2003) 10 patients
were included in the currentpilot study.The medianage was
54 years (range 31–72 years). Tumor volumes ranged
between 2.1 and 10.2 cm3 (mean: 5.9 cm3) and the total
volume light fluence ranged between 939 and 2,304 J/cm3
(mean: 1,405 J/cm3) (Table 1). A complete irradiation of the
tumor volume was possible in all of these patients using four
to six fibers per patient. The accuracy of the final fiber
position (as compared to the original treatment plan) was in
the range of 2 mm, as judged by X-ray control. Perioperative
morbidity was not observed. A symptomatic early or delayed
treatment induced edema did not occur during the follow-up
period and steroid medication was only applied periopera-
tively (during the first 3 days after surgery).
Fig. 3. Iso-fluence rates of a cylindrical light diffuser calcu-
lated by Monte-Carlo simulations.
TABLE 1. Patient Characteristics, Treatment Parameters, and Survival of the 10 Patients Included in
the Pilot Study
Patient
ID Age KPS pre-Op Tumorlocation Side
Tumor
volume (ccm)
Total light
fluence (J)
Volume light
fluence (J/ccm)
Survival time
(months)
1 31 100 Frontal Left 6.9 7,200 1043 49
2 69 80 Parietal Right 4.8 5,700 1188 4
3 72 90 Temporal Right 4.5 7,500 1667 11
4 42 90 Fronto-temporal Left 2.1 4,320 2057 32
5 54 90 Parietal Right 6.3 6,600 1048 7
6 54 100 Frontal Left 10.2 11,520 1129 5
7 56 80 Fronto-temporal Left 9.9 10,080 1018 39
8 57 90 Parietal Left 2.9 4,800 1655 27
9 32 80 Frontal Left 9.2 8,640 939 17
10 50 90 Temporal Right 2.5 5,760 2304 13
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MRI Follow-Up After iPDT
Early postoperative MRI (at day 1 after surgery) showed
a complete resolution of the contrast enhancement of the
treated lesion in seven patients and a partial resolution in
the other three. Typically, transient contrast enhancement
was seen again at day 7 after treatment at the boundary of
the treatment volume. It was accompanied by a moderate
increase of the peri-lesional edema, which slowly resolved
spontaneously during the first 3 months after surgery. A
representative example is given in Figure 5.
Survival
The 1-year-survival rate was 60% (median survival: 15
months). Four patients lived longer than 24 months and
two of them are still alive (Fig. 6). Last follow-up evaluation
revealed a high KPS of the survivors (80).
DISCUSSION
A prerequisite for iPDT as a possible minimal invasive
treatment option for selected patients with a circumscribed
malignant glioma recurrence (after previously applied
standard therapy) is the application of a PS with a selective
tumor uptake and the availability of an accurate and
reproducible irradiation scheme. In the current study an
irradiation scheme was developed on the basis of theore-
tical models and the feasibility of its clinical implementa-
tion was tested thereafter. It was hypothesized that the
combination of a new and selectively working PS (5-ALA
induced PPIX) with stereotactic techniques enabling both a
3-D-dosimetry and optimal placement of the laser fibers
thereafter would lead to controlled treatment effects.
Photosensitizer
Inefficient tumor control and severe side effects of the
therapy have been described for iPDT if it is based on
Fig. 4. Screen shot of the 3-D-planning showing excellent
agreement between the estimated treatment margin (black
line) and the tumor margin (white line). Axial plane (a) and
sagittal plane (b).
Fig. 5. Series of contrast-enhanced MRI-scans (T1 weighted) of a patient treated with iPDT.
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synthetic porphyrins such as hematoporphyrin derivative
(HpD) or Photofrin1. For example, five out of eight
glioblastoma patients treated by Powers et al. [13] had a
recurrence within two months after iPDT (using Photo-
frin1), while at the same time all patients suffered from
treatment-induced edema and prolonged skin sensitiza-
tion. Similar results have been reported by other groups
[15,16].
Unselective effects of HpD and Photofrin1 were also
described in animal studies [12,33–37] and have been
related to both the inhomogeneous distribution of the PS
within the tumors and extensive leakage of the PS to the
surrounding normal tissue (via peritumoral edema bulk
flow). PDT by means of 5-ALA induced PPIX is expected to
induce less often and less severe side effects for several
reasons: (1) The drug applied systemically (5-ALA) is itself
not phototoxic, (2) 5-ALA induced PPIX has been shown to
accumulate selectively within the tumor, and (3) a
significant redistribution of the PS by peritumoral edema
bulk flow does not seem to occur. Olzowy et al. [17], for
example, who investigated treatment effects of PDT by
means of 5-ALA induced PPIX in an experimental glioma
model, found selective phototoxic effects within the tumor
(coagulative or hemorrhagic necrosis), whereas the damage
to the normal or perifocal edematous tissue was negligible.
Exactly these favorable characteristics of 5-ALA have led to
a re-evaluation of iPDT as a potentially minimal invasive
treatment modality and are an important prerequisite for
accurate treatment planning.
Irradiation Scheme and Treatment Planning
A reproducible irradiation scheme for iPDT with 5-ALA
induced PPIX has not been provided in the literature so far.
Thus, uncertainties persist as to the temperature and light
distribution within the treatment volume and the appro-
priate total light fluence.
In a first step, it was aimed to determine an interfiber
distance that reliably excludes tissue heating beyond the
428C level. Light dosimetry—in a second step—was mainly
determined by clinical parameters such as the duration and
invasiveness of the surgical procedure. A treatment time in
the range of 1 hour was considered to be appropriate. Due to
the selectivity of the applied PS and its photobleaching with
fluences in the range of 100 J/cm2,side effects due to an
excessive fluence were not expected to occur and an upper
limit for the applied fluence was therefore not considered
necessary to define.
Temperature and light distributions during iPDT were
analyzed by Monte-Carlo simulations and then indirectly
validated by clinical data. Online measurements were not
performed. The significance of such online measurements
might be limited due to heterogeneous optical penetration
depths within the tumor and the brain/tumor interface [28]
and inaccurate position measurements of the implanted
sensors. Moreover, the interstitial placements of sensors
might be associated with an additional risk for the patient.
Therefore, simulations were preferred in the current study.
As optical parameters for malignant glioma recurrences
are not available, the optical properties of BAT were used,
which might be considered an adequate model for a
mutimodally treated glioma; based on this model, different
sets of input parameters were tested to check for the effects
of a possible heterogeneity.
As expected, the LITCIT simulations showed that the
degree of temperature increase within the treatment
volume depended on the interfiber distance. An inter-fiber
distance of 9 mm did not result in a temperature increase
above 428C even in the case of unfavorable input para-
meters and was therefore judged to be safe. A larger
distance between the fibers is not advisable, as the steep
decrease of the fluence rate from the fiber surface has to be
compensated with much longer irradiation times.
With an interfiber distance of 9 mm, a distance from
fibers to tumor margin of 3 mm, a light power of 200 mW/cm
diffuser length, and a treatment time of 1 hour, the
individually applied total fluence can be calculated depend-
ing on the number of diffusers. At the tumor margin, which
is one penetration depth away from the light diffusers, a
fluence of 1,870 J/cm2 can be expected. This fluence may
appear very high as compared to fluences commonly used in
plane wave irradiation [10,38]. However, the fluence in
cylindrical light diffuser irradiation decreases more rapidly
to the periphery than in plane wave irradiation: The fluence
at a distance of 6 mm (one penetration depth outside the
treatment volume) from the applicator’s surface decreases
to a value of 400 J/cm2 and equals the fluence obtained in 3
mm depth in plane wave irradiation using a fluence rate of
200 mW/cm2 and a treatment time of 1,000 seconds. These
estimations imply that high fluences must be expected to be
applied to the adjacent normal brain tissue outside the
treatment volume. However, due to the absence of a
significant photosensitization of normal brain tissue as a
consequence of a selectively working PS [23], significant
side effects of the 5-ALA iPDT approach were not expected
to occur.
To confirm the results of the Monte-Carlo simulations,
online measurements of temperature, fluence rate, PS
Fig. 6. Kaplan–Meier survival curve for survival post-iPDT
calculated from date of surgery of the 10 patients included in
the pilot-study.
INTERSTITIAL PHOTODYNAMIC THERAPY 391
concentration, and oxygenation would be helpful. Johans-
son et al. [39] presented such an online measurement
system, which has been validated in animal studies.
Thompson et al. [40] lately reported about a novel approach
for a therapy system with combined on-line dosimetry,
being able to monitor fluence rate, sensitizer fluorescence,
and oxygenation. These combined systems seem to have a
high potential for a reliable treatment dosimetry in iPDT.
However, the fibers used in these systems were bare fibers
and thus, the described computer model cannot be easily
adapted to cylindrical diffusers used in the current study.
Clinical Implementation
An image-based computer-assisted protocol for iPDT of
intracranial neoplasms has been already described by
Origitano and Reichman [14]. Photoactivation was done
intracavitarily or interstitially by inserting multiple fibers
using the PS Photofrin-II. Even though the authors
demonstrated the successful clinical implementation of
their system within the framework of a phase I study, they
did not provide data concerning the optimal interfiber
distance, the corresponding temperature and light distri-
butions, and the side effects of the applied therapy. In the
present study, the customized 3-D planning software
proved to be very useful for the determination of the exact
fiber positions within the tumor volume. The accuracy of
the final fiber position was always in the range of 2 mm and
the treatment volume matched accurately the tumor
volume in every single patient of this series. However,
both the treatment-planning and stereotactic implantation
procedure turned out to be complex and rather time
consuming. The development of a computer-based optimi-
zation algorithm is therefore desirable and would help to
simplify and standardize the planning procedure.
Imaging Changes After iPDT
The radiographic changes observed in the 10 treated
patients were impressive with early MRI (within 24 hour)
follow-up showing a complete resolution of the contrast-
enhanced lesion in seven patients (a representative
example is given in Fig. 5) and a partial response in the
other three. This very early response might be explained by
a treatment induced swelling of endothelial cells leading to
a temporary ‘‘sealing’’ of the blood-brain-barrier (BBB).
However, later MRI-scans (approximately after 1 week)
showed a recurrent contrast enhancement at the boundary
of the treatment volume indicating a transient leakage in
the BBB, which was accompanied by moderate increase of
the peri-lesional edema.
Median survival was 15 months in the current series and
four patients lived longer than 24 months. Generally, a
median survival in the range of 6–8 months is expected for
patients with malignant glioma recurrences. Whether the
encouraging survival data of this series should be related to
effects of patient selection, treatment efficacy or both could
not be resolved at this moment. Beyond direct phototoxic
effects of iPDT (such as apoptosis and necrosis) activation of
the immune response after PDT has been reported (e.g.,
increased expression of heat shock proteins), which
deserves further experimental and clinical evaluation
[41–43].
Risk of iPDT
The total applied light fluences in this study (4,320–
11,520 J) are very high, yet there was no surgery or
treatment-related morbidity or mortality in our patient
series, whereas Krishnamurty [15] reported about
increased risk of neurologic injury and permanent deficits
at a total applied light dose above 4,000 J as compared to
light doses between 3,700 and 4,000 J after administration
of Photofrin1. In our patient series there was no enhanced
treatment-induced brain edema and steroid medication
was only applied for 3 days as routinely done in other
stereotactic procedures in our institution. The absence of
side effects supports the concept of a selectively working
PS such as 5-ALA induced PPIX and the postulated im-
plications of the applied irradiation scheme: Significant
treatment-induced hyperthermia (428C or more) and/or
unwanted accumulation and activation of 5-ALA outside
the tumor tissue apparently did not occur.
SUMMARY AND PERSPECTIVE
The intention of the present study was to establish an
implementation concept for iPDT with 5-ALA-induced
PPIX for minimally invasive treatment of patients with
small malignant glioma recurrences. The development of a
3-D treatment-planning was based on optical and thermal
simulations. A modus operandi was established to implant
stereotactically up to six cylindrical light diffusers within
the tumor in accordance with the created treatment plan.
This treatment procedure ensured a minimum threshold
light fluence within the entire tumor thereby avoiding
significant hyperthermia (428C or higher). Clinical imple-
mentation and outcome support the theoretical assump-
tions used for the determination of the irradiation and the
postulated selective uptake of 5-ALA-induced PPIX: No
side effects of the therapy were observed during the follow-
up period. A further (prospective) clinical evaluation with a
greater patient cohort is needed, which is the subject of an
ongoing study at our institution.
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Abstract Glioblastoma multiforme continues to be a
devastating disease despite modest improvements in
survival achieved at present, and there is an urgent need for
innovative treatment concepts. Five-aminolevulinic acid
(ALA) is a drug which induces protoporphyrin IX accu-
mulation in malignant gliomas and has been explored for
fluorescence-guided resections of these tumors. ALA is
also under investigation as a photosensitizer. We report a
case of a patient with prior left frontal glioblastoma
multiforme treated by surgery, radiation and chemother-
apy, who developed a remote lesion in the left insula,
which was refractory to secondary treatments. In a com-
passionate use setting she was treated by oral application of
ALA (20 mg/kg bodyweight), and stereotactic photother-
apy achieved by positioning four laser diffusors using
3-dimensional irradiation planning, and a 633 nm diode
laser. The lesion disappeared 24 h after therapy. Circum-
ferential contrast enhancement was observed at 72 h,
which disappeared in the course of subsequential months.
Edema resolved completely. The patient is still free of
recurrence 56 months after treatment, demonstrating an
impressive and long-lasting response to this novel mode of
therapy.
Keywords ALA  Local therapy  Malignant glioma 
Photodynamic therapy  Porphyrins  Stereotactic surgery 
Stereotactic  Interstitial  Glioblastoma 
5-aminolevulinic acid  Protoporphyrin IX
Introduction
Desptie recent advances in the therapy of patients with
glioblastoma multiforme [1] median survival is still
restricted to 15 months. In recurrent disease, the best
possible established second line-treatments, apart from
surgery, are local chemotherapy with BCNU wafers [2] or
temozolamide chemotherapy [3], which result in an overall
survival of less than 8 months. Novel therapies, such as
immunotoxins, administered via convection-enhanced
delivery [4], or gene therapy [5] have so far failed phase III
evaluations. Therefore, new treatment concepts are des-
perately needed.
We have explored the endogenous heme precursor
5-aminolevulinic acid (ALA) for fluorescence-guided
resections of malignant gliomas because ALA leads to the
synthesis and accumulation of highly fluorescent protopor-
phyrin IX within malignant glioma tissue experimentally [6]
and in patients [7, 8]. The usefulness of this approach has
been validated in the framework of a prospectively-
randomized phase III study [9] and approval has
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recently been granted for the European Union (http://
www.emea.europa.eu/pdfs/human/opinion/36383007en.pdf).
Apart from its fluorescence, protoporphyrin IX is also a
strong photosensitizer. The photosensitizing properties of
the compound had been in investigated vitro [10–13] and
in vivo [14, 15], and selective destruction of sensitized
malignant glioma tissue has been noted. Thus,
ALA-induced protoporphyrin IX accumulation in malig-
nant glioma cells appear to render these selectively
susceptible to phototherapy, provided they are exposed to
sufficient light. To this end, we have recently published an
overview of the technical approach to the problem of
treating deep-seated tumors [16]. This technique utilizes a
software platform for 3-dimensional planning and stereo-
tactic implantation of light diffusors into sensitized
malignant glioma tissue. The first patients subjected to this
method harbored the distant recurrence of a previously
resected glioblastoma multiforme treated by adjuvant
radio- and chemotherapy, which was unresponsive to sec-
ond-line interventions. She responded dramatically to 5-
ALA-phototherapy and remains without recurrence more
than 56 months after treatment.
Case material and results
In October 2002, a 31-year-old female consulted our neuro-
oncology service. In April 2001, she had suffered a grand
mal seizure. She was diagnosed with left frontal glioblas-
toma multiforme and underwent surgery 2 days later.
Surgery was followed by conventional external beam,
fractionated radiotherapy of 60 Gy to the tumor bed and
2 cm margin, delivered in 30 fraction of 2 Gy. Radiation
therapy was followed by two cycles of PCV (procarbacine,
CCNU, vincristine) chemotherapy. During the second
cycle she developed an allergic reaction to procarbacine, so
that chemotherapy was continued with temozolamide,
initiated with 150 mg/m2/day for five consecutive days
every 28 days. During the second to fourth cycles the dose
was increased to 200 mg/m2/day on the first 5 days. After
four cycles the patient wished to temporarily discontinue
treatment. MRI exams obtained in three monthly intervals
after surgery were unremarkable and without contrast
enhancing lesions. In April 2002 the patient again suffered
a grand mal seizure. MRI obtained at this time now
demonstrated second, remote lesion in the left insula with a
diameter of 5 mm. Since surgery was not considered an
option, the lesion was treated by a stereotactic conformal
radiotherapy boost of 40 Gy, which was applied to the new
lesion and its 2 cm margin. Two additional cycles of
chemotherapy with temozolamide were then initiated.
Nevertheless, MRI obtained after these therapies revealed
progressive disease with a tumor diameter of 2.2 cm.
At the time of her initial consultation at our center, the
patient’s lesion measured 2.5 cm in its greatest diameter
and was accompanied by marked edema, extending into the
frontal and occipital lobes (Fig. 1), with mild midline
displacement. The patient was without deficits and in good
clinical condition, with a Karnofsky Performance Score of
100. She was offered treatment in the setting of a number
of experimental protocols, including treatment according to
a novel protocol for interstitial, 5-ALA-phototherapy for
which a pilot study was in preparation. She was selected to
participate in the latter study and expedited permission to
perform treatment was obtained via the ethical committee
of the Ludwig–Maximilians-University, Munich.
Treatment was performed as previously described [16].
Briefly, the patient was placed on 3 9 8 mg dexamethasone
for 2 days prior to therapy. About 20 mg/kg bodyweight
5-ALA (medac, Wedel, Germany) were administered orally
3 h prior to the procedure. Under local anesthesia and mild
diazepam sedation, stereotactic biopsy of the lesion was
performed, confirming glioblastoma multiforme (Fig. 2).
Using @target software version 1.19 (Brainlab AG, Gil-
ching), 3-dimensional irradiation planning was carried out
and four glasfiber light guides (diameter 600 lm) were
Fig. 1 (a) MR prior to initial surgery April 2001; (b) left frontal
surgical cavity after tumor removal (October 2002); (c) remote
secondary lesion with hemispheric edema (t1 weighted MR with
constrast and t2-weighted MRI)
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implantated into the tumor. These were tipped with diffu-
sors measuring 2 cm in length. During light irradiation fiO2
was increased to 100%. For a tumor volume of 7.9 ccm a
total energy of 1,200 J/ccm diffuser length was applied
using a 633 nm Ceralas PDT Diode Laser (biolitec AG,
Jena, Germany) at a power 200 mW/cm of light diffusor.
MR images were obtained 24 h later (Fig. 3), then at 7, 15
and 27 days after the procedure. The MRI obtained at 24 h
demonstrated almost complete disappearance of contrast-
enhancement. At 7 days, a small rim of marginal
enhancement had appeared (Figs. 4–6). Thereafter, con-
trast-enhancement slowly disappeared. On t2-weighted
imaging, edema was mildly increased 24 h after the pro-
cedure and dissipated within the following weeks.
Clinically, the course of the patient was unremarkable and
then she retained her fully functional status. She was dis-
charged 5 days after surgery. Throughout the 2 weeks
following the procedure, dexamethasone was gradually
tapered and stopped. The patient was followed closely
thereafter. After 6 months ACNU (90 mg/m2 iv, day 1) and
VM 26 VM26 (60 mg/m2, days 1–3; both drugs given in
six-week intervals) was initiated at an outside center. Over a
period of 1 year five cycles were administered with several
interruptions due to myelosuppresion. The patient was then
enrolled in a protocol with hydroxyurea and imantinib in the
beginning of 2004 (400 mg once daily and hydroxyurea
500 mg twice daily). Due to myelosuppression hydroxyurea
was administerd at a reduced dose of 500 mg once daily.
Anemia was treated by two weekly applications of eryth-
ropoietin. This therapy was continued until the end of 2006.
The patient is still free of recurrence at time of last
contact (July 2007).
Discussion
Photodynamic therapy, that is, the combination of photo-
sensitizer and light for sensitization and destruction of
malignant glioma cells has been attempted in the past using
synthetic porphyrins such as hematoporphyrin derivative
(HpD) or Photofrin1 (as reviewed in Madsen and Hir-
schberg [17]). Stereotactic applications have also been
studied, for instance by Powers et al. [18]). However, in
Fig. 2 Photomicrograph of H & E-stained operative specimen from
serial stereotactic biopsy of left insular lesion, demonstrating capillary
proliferation, cell anaplasia and necrosis consistent with gliolastoma
multiforme
Fig. 3 MR images 24 h after phototherapy. (a) t1-weighted sequence
with contrast. Note complete loss of contrast-enhancement.
(b) t2-weighted image. Edema appears mildly increased compared
to the preoperative image
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that study efficacy was limited, with five out of eight
glioblastoma patients suffering a recurrence within
2 months after therapy, with some concern about treatment
related side-effects, such as brain edema and prolonged
skin sensitization. This experience has been shared by
others [19, 20]. In this context, animal experiments suggest
that impaired efficacy using synthetic porphyrins may be
related to inhomogeneous tumor distribution of sensitizer,
whereas enhanced edema may be due to the unspecific
sensitization of peritumoral tissue as a consequence of
unwanted leakage across the blood–brain barrier within
malignant glioma [21–26]. Propagation of sensitizer with
edema bulk flow will then render peritumoral tissue sen-
sitive to light, causing unwanted brain damage.
Five-aminolevulinic acid (ALA) is conceptually differ-
ent compared to the synthetic porphyrins. ALA is a
prodrug, which is taken up and metabolized into photoac-
tive protoporphyrin IX within malignant glioma cells. The
advantages are selective tumor sensitization, lack of
Fig. 4 MR images 7 days after phototherapy. (a) t1-weighted sequence
with contrast. Note contrast-enhancement circumferential to the intial
lesion. (b) t2-weighted image
Fig. 5 MR images 33 days after phototherapy. (a) t1-weighted sequence
with contrast. (b) t2-weighted image
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unspecific sensitization of adjacent brain [15] and only
brief skin sensitization (24 h). Furthermore, very recently
approval has been granted within the European Community
for the use of ALA for fluorescence-guided resections of
malignant gliomas (http://www.emea.europa.eu/pdfs/
human/opinion/36383007en.pdf), suggesting a combina-
tion fluorescence-guided resection with phototherapy as an
attractive treatment option.
The benefits of ALA compared to synthetic porphyrins
have now prompted a re-evaluation of stereotactic photo-
therapy using this drug. Technical details of a first pilot
series of patients suffering recurrent malignant gliomas
have recently been published, including an overview of
their clinical outcomes and safety [16]. Median survival in
this series of patients was approximately 15 months.
The patient reported here was the first patient in that
series and served as proof of principle for the concept of
stereotactic phototherapy using ALA and 3-dimensional
planning of laser light delivery using customized software.
The low light fluences and geometrical location of diffu-
sors used in our study ruled out thermic effects to be the
cause of this efficacy. Experimental modelling using worst
case assumptions have demonstrated temperatures to
remain under 42 in the irradiated tissue [16].
Remarkably, in this patient as in the other patients of the
intial series, contrast-enhancement related to tumor tissue
was no longer evident on MR imaging obtained only 24 h
after the procedure, which can be taken to represent
‘‘complete response’’. The reason for this phenomenon is
unclear. Abolishment of contrast–enhancement might
represent an acute interruption of tumor perfusion and one
possible explanation could be treatment-induced swelling
of tumor and endothelial cells with consecutive vessel
occlusion. On the other hand, MR images obtained after
7 days again revealed contrast–enhancement, albeit not
within the volume of the original tumor. Rather, enhance-
ment was located outside the original tumor margins and
was probably indicative of reactive changes. The resolution
of secondary enhancement within successive months sup-
ports this assumption.
The most remarkable observation in the present case,
however, was the length of disease stabilisation, now
lasting 57 months after treatment and approximately
75 months after initial diagnosis in a patient with remote
recurrence of glioblastoma and multimodal treatment fail-
ures. It cannot be ascertained that ALA-phototherapy was
the only factor involved in this stabilisation, because the
patient was subsequentially exposed to two further modes
of chemotherapy, beginning 6 months later. However, the
remarkable initial response strongly encourages the view
that ALA-phototherapy was efficacious and durable. Fur-
thermore, assuming phototherapy to be responsible for
long-acting stabilisation, mere cytoreduction by drug and
laser light interaction may not be the only mechanism
playing a role. Beyond direct phototoxic effects, such as
necrosis, activation of an immune response (e.g., increased
expression of heat shock proteins) has been reported after
ALA-mediated phototherapy in other organ systems
[27–29]. Furthermore, suppression of survival factors and
activation of proteases for apoptosis has also been sug-
gested as a possible mechanism [11].
Fig. 6 MR images 38 months after phototherapy. (a) t1-weighted
sequence with contrast. (b) t2-weighted image
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Although preliminary results of the pilot trial in which
the patient reported here participated have been published
previously [16], that report provided no details on the
clinical history nor the pathologic findings for this partic-
ular patient. Therefore, the patient has been presented here
separately to allow readers to make independent judgments
concerning the long-standing response of her tumor.
Conclusions
Phototherapy using ALA as sensitizer demonstrates bio-
logic activity, as demonstrated by the patient reported here,
who suffered remote recurrence of glioblastoma multi-
forme and had failed augmental radio-and chemotherapy.
This response has been associated with a durable clinical
and radiographic stabilization. Toxicity was not observed.
The observation strongly warrants further investigation into
the clinical benefits of this approach, as well as the
mechanisms involved.
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